Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and [...]
Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t [...]
There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]
Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an [...]
In General the use of a PSA value in excess of 4.0 µg/L is considered a clinical indicator for men at risk for prostate cancer. But, is this a good prognostic indicator in men who are HIV Positive? Researchers found that PSA was highly predictive of prostate cancer in men with HIV; however the commonly [...]